Compare CVS Health Corp (CVS) vs HP Inc (HPQ) Price & Performance

CVS Health trades at $86.16, down 2.04% for the day, amid a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst consensus is overwhelmingly positive, with 35 of 41 analysts rating the stock a Buy and a consensus price target of $111.20, implying significant upside. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.

The outlook for CVS remains favorable based on fundamental strength and analyst optimism, but risks include reimbursement pressure, regulatory scrutiny, and a high debt load. The stock's current valuation metrics, such as a P/E of 23.17 and P/S of 0.27, appear reasonable relative to historical levels, supporting a constructive view for long-term investors despite near-term technical weakness.

HPQ trades at $30.2, down 6.33% on the day, amid concerns over a projected mid-single-digit PC sales decline in 2027. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels are mixed. Fundamentally, HPQ maintains solid profitability with a 4.14% net margin and attractive valuation at a P/E of 12.38 and P/S of 0.51. Recent earnings beats highlight operational strength, but negative shareholder equity and high liabilities pose balance sheet risks.

The outlook is cautious; while HPQ's dividend yield of 3.82% and consistent cash flow provide income appeal, near-term headwinds from PC market softness and competitive pressures may limit upside. Analyst consensus is mixed with a $25.75 price target below current levels, suggesting limited near-term growth potential. Investors should weigh stable cash generation against cyclical industry risks and elevated debt.